IOBT Stock Risk & Deep Value Analysis
IO Biotech Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About IOBT Stock
We analyzed IO Biotech Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran IOBT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
IOBT Risk Analysis & Red Flags
What Could Go Wrong
The company has filed for Chapter 7 bankruptcy liquidation, meaning its assets will be sold to pay off creditors, and common stockholders are highly unlikely to receive any distribution, resulting in a total loss of investment.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Chapter 7 bankruptcy liquidation filed on March 31, 2026
- ⚠
Shutdown of all operations and termination of all employees
- ⚠
Resignation of all directors and management
- ⚠
Failed Phase 3 trial and FDA advice against BLA submission (Sep 2025)
- ⚠
Critically short cash runway exhausted leading to insolvency
Upcoming Risk Events
- 📅
Finalization of Chapter 7 liquidation process
- 📅
Official delisting from OTC markets
When to Reconsider
- 🚪
Any remaining shares should be considered valueless; the sell signal has already occurred with the bankruptcy filing.
- 🚪
Confirmation of no distribution to common shareholders from the bankruptcy court.
Unlock IOBT Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does IO Biotech Inc (IOBT) Do?
Market Cap
$3.45M
Sector
Healthcare
Industry
Biotechnology
Employees
78
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFß1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark.
Visit IO Biotech Inc WebsiteInvestment Thesis
There is no investment thesis for IOBTQ. The company has filed for Chapter 7 bankruptcy liquidation, making any investment a guaranteed total loss for common shareholders. Investors should avoid this stock entirely.
Is IOBT Stock Undervalued?
Unlock the full AI analysis for IOBT
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
IOBT Price Targets & Strategy
12-Month Target
$0.00
Bull Case
$0.00
Bear Case
$0.00
Valuation Basis
Common stockholders in Chapter 7 liquidation typically receive $0.00 as assets are distributed to creditors in priority order.
Entry Strategy
Avoid at all costs; no entry strategy is recommended.
Exit Strategy
Any remaining shares should be considered a total loss. No viable exit strategy for recovering value.
Portfolio Allocation
0% for all risk profiles (Conservative/Moderate/Aggressive).
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is IOBT Financially Healthy?
Valuation
P/E Ratio
-0.04
Price/Book
3.79
Profitability
Return on Equity
-465.36%
EPS
$-1.34
Balance Sheet
Current Ratio
3.33
Quick Ratio
3.18
Debt/Equity
42.86
Cash & Equivalents
$30.66M
Cash Flow
Free Cash Flow
-$81.06M
EBITDA
-$93.49M
Other
Beta (Volatility)
0.66
Does IOBT Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
The company's intellectual property and platform failed to translate into a viable product and ultimately led to bankruptcy, demonstrating a complete lack of durable moat.
Moat Erosion Risks
- •Clinical trial failure
- •Lack of funding and insolvency
IOBT Competitive Moat Analysis
Sign up to see competitive advantages
IOBT Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish (Reflecting total loss, likely some speculative trading due to OTC listing)
Institutional Sentiment
Negative (Institutions like HBM Healthcare Investments, if they still hold, would have written off this investment)
Insider Activity (Form 4)
No Form 4 filings reported in last 90 days. Insider ownership was 2.30% (latest annual proxy), but all directors have resigned post-bankruptcy.
Options Flow
Normal options activity (likely minimal to non-existent given the company's status)
Earnings Intelligence
Next Earnings
None scheduled; company in Chapter 7 liquidation
Surprise Probability
Low (No operations, no earnings)
Historical Earnings Pattern
N/A - Company is defunct.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A
Market Share Trend
Losing (Company has ceased operations and lost all market share potential)
Valuation vs Peers
N/A - Company is bankrupt.
Competitive Advantages
- •N/A
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive IOBT Stock Higher?
Near-Term (0-6 months)
- •No positive catalysts; ongoing Chapter 7 liquidation process (0-6 months)
Medium-Term (6-18 months)
- •No positive catalysts; asset sale and creditor distribution (6-18 months)
Long-Term (18+ months)
- •No positive catalysts; permanent dissolution of the company (18+ months)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for IOBT?
- ✓
None relevant for investment purposes; monitoring of bankruptcy proceedings will confirm the complete loss of shareholder value.
- ✓
Confirmation of asset distribution details from the bankruptcy court.
Bull Case Analysis
See what could go right with Premium
Competing with IOBT
See how IO Biotech Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
IO Biotech Inc IOBT | $3.5M | 0.1 | -0.0 | — | — | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How IO Biotech Inc Makes Money
Prior to bankruptcy, IO Biotech Inc was a clinical-stage biopharmaceutical company focused on developing novel immuno-oncology therapies, specifically cancer vaccines, utilizing its proprietary T-win® platform. Its primary revenue generation model would have involved licensing agreements, milestone payments from partners, and eventual product sales if its lead candidates (like IO102-IO103) achieved regulatory approval. However, the company has ceased all operations due to Chapter 7 bankruptcy, rendering this business model defunct.
Read Full Business Model BreakdownFAQ
What is the DVR Score for IO Biotech Inc (IOBT)?
As of April 14, 2026, IO Biotech Inc has a DVR Score of 0.1 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of IO Biotech Inc?
IO Biotech Inc's market capitalization is approximately $3.5M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does IO Biotech Inc use?
IOBT is the ticker symbol for IO Biotech Inc. The company trades on the NMS.
What is the risk level for IOBT stock?
Our analysis rates IO Biotech Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of IOBT?
IO Biotech Inc currently has a price-to-earnings (P/E) ratio of -0.0. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
How often is the IOBT DVR analysis updated?
Our AI-powered analysis of IO Biotech Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 14, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for IOBT (IO Biotech Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.